Cardiosense, a digital health company pioneering AI-enabled solutions for cardiac disease management, announced a new subgroup analysis of clinical data from the SEISMIC-HF I study at the Cardiovascular Research Foundation’s 2025 annual Transcatheter Cardiovascular Therapeutics scientific symposium. The analysis examined the prescribed medications for symptomatic patients hospitalized with acute decompensated heart failure (ADHF), highlighting the potential that noninvasive pulmonary capillary wedge pressure (PCWP) assessment could have in guiding individualized therapy adjustment in the hospital setting.
Health Technology Insights: Avextra Backs Phase II Trial on Cannabis for Neuro Diseases
Anjan Tibrewala, MD, of Northwestern Medicine’s Bluhm Cardiovascular Institute, presented the analysis as a moderated abstract titled, “Low Filling Pressures in Patients with Acute Exacerbation of Heart Failure with Reduced Ejection Fraction (HFrEF) as Identified with a Novel Sensor: A Sub-Analysis of the SEISMIC-HF I Study”(abstract TCT-558). Key findings suggest that a noninvasive method for volume assessment could potentially reduce excessive diuretic use and help providers optimize guideline-directed medical therapy (GDMT). The analysis in 76 patients with HFrEF hospitalized with ADHF showed:
Health Technology Insights: Rani Therapeutics Adds New Members to Board
- 29 patients (26%) with a catheterization-measured PCWP ≤15 mmHg, suggesting that low filling pressures occur frequently and the reflex treatment of increased diuretic use in the setting of physical exam findings of congestion may not be appropriate
- Among those 29 patients with low-to-normal PCWP, 19 (66%) were receiving diuretic therapy and only 10 (34%) were on quadruple guideline-directed medical therapy (GDMT)
“Managing volume status is one of the most challenging and consequential aspects of care in heart disease, even in the hospital where volume can only be accurately assessed invasively in the cath lab or intensive care unit today,” said John Martin, MD, MBA, EVP and Chief Medical Officer of Cardiosense. “Our SEISMIC-HF I analysis at TCT this year underscores the need for more accessible, noninvasive methods of volume assessment to help guide clinical decision making. We have the potential to aid providers in better optimizing medical therapy with our noninvasive wearable CardioTag™ device and PCWPAI algorithm.”
Health Technology Insights: State Announces Promotion of Brandon Huisman to Vice President
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source – businesswire
